Be Biopharma has raised $92 million to support the first-in-human Phase 1/2 trial of BE-101, which is made to lower bleeding ...

Columnist Jennifer Lynne interviews Debbie Murray, a New Yorker whose hemophilia B diagnosis didn't occur until she was almost 51.

Now that his adult sons are managing their own hemophilia care, columnist Joe MacDonald is able to consider moving for a job.

Two hemophilia patients in the U.S. who struggled for years with bleeds have been given Hemgenix, the first gene therapy ...

Columnist G Shellye Horowitz wasn't surprised to learn she had osteopenia, as her bleeding disorder increases her risk of low ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...

Prophylactic, or preventive, treatment with factor VIII (FVIII) replacement therapy for four years reduced annual bleeding rates by 91% for people with severe hemophilia A, a study from Taiwan ...

When I tell people I’m a woman with hemophilia, I’m often met with the same response: “Well, that is really unusual. It’s rare for women to have hemophilia!” This ubiquitous misconception is the bane ...

Observing her husband, columnist Alliah Czarielle sees that getting older is a great equalizer, as more in their community have health woes.

MacDonald worries about her adult son being complacent when it comes to administering his hemophilia medication.